Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Genetically Risk-Stratified Combination of Venetoclax, Ibrutinib and Rituximab (With and Without Navitoclax) in Patients With Relapsed and Refractory Mantle Cell Lymphoma (AIM2)

NCT05864742 is registered in ClinicalTrials.gov with Peter MacCallum Cancer Centre, Australia as lead sponsor.

NCT NCT05864742
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05864742 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Genetically Risk-Stratified Combination of Venetoclax, Ibrutinib and Rituximab (With and Without Navitoclax) in Patients With Relapsed and Refractory Mantle Cell Lymphoma (AIM2)
Lead sponsor
Peter MacCallum Cancer Centre, Australia
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 7, 2023
Completion date
June 1, 2029
Enrollment
40 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

mantle cell lymphoma refractory